News Hub | News Direct

News Release

Delivra Health Brands sees 112% increase in 1Q 2024 revenue

Delivra Health Brands Inc.

Delivra Health Brands CEO Gord Davey joined Stephen Gunnion from Proactive to share news the company has released its financial performance for the first quarter of 2024, and the results are impressive. The company reported a 112% increase in net revenue for the quarter, largely driven by robust sales of Dream Water in the United States. This surge in sales was primarily attributed to the favorable timing of increased purchase order activity in the US market. Notably, the company also experienced improvements in gross profit and gross profit margins, achieving a 52% gross profit margin compared to 51% in the same period last year. These positive outcomes can be attributed to lower sales fees and reduced indirect cost of sales relative to the increase in revenue. Looking ahead to 2024, Delivra Health Brands has ambitious plans. These include investments in customer-specific programs, a strategic focus on enhancing its e-commerce strategy, the launch of innovative products, and efforts to improve distribution across various channels. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

December 04, 2023 01:35 PM Eastern Standard Time

Video

News Release

Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA

Theralase Technologies Inc.

Theralase Technologies Inc. CEO Roger DuMoulin-White, joined Proactive's Stephen Gunnion to discuss the company's third-quarter 2023 operational highlights. The company successfully raised $1.17 million, crucial for advancing its Phase II clinical study targeting non-muscle invasive bladder cancer, particularly Bacillus Calmette-Guérin (BCG)-Unresponsive cases. The study's data shows promising superiority over FDA-approved drugs from major pharmaceutical companies, making it a groundbreaking development for Theralase. DuMoulin-White detailed the unique approach, utilizing a drug-device combination involving a light-sensitive drug instilled into the bladder. This innovative method selectively targets cancer cells, minimizing damage to healthy cells, a departure from traditional pharmacological approaches. Currently working on its pre-Breakthrough Therapy Designation (BTD) with the FDA, Theralase is aiming for formal BTD in early 2024. Dumoulin-White highlighted the company's focus on non-dilutive financing, potential partnerships, and completing the primary study treatment for around 100 patients by the end of 2024. Successful completion could lead to an FDA decision, ideally by the end of 2026, potentially accelerated with priority review. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

December 04, 2023 01:16 PM Eastern Standard Time

Video

VinBrain to launch AI-centric solutions to save lives and advance precision care at RSNA 2023

Vingroup

CHICAGO, US - Media OutReach - 4 December 2023 - VinBrain, a leading AI HealthTech company based in Vietnam, funded by Vingroup has joined in the largest medical meetings and exhibition of North America, RSNA 2023. Unveiling two impactful AI-centric solutions during the event - DrAid™ Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid™ Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone. RSNA 2023: Leading through Change in AI for diagnosis, treatment, care, interoperability The Technical Exhibits within the 109th Scientific Assembly and Annual Meeting Radiological Society of North America (RSNA), IL, USA have ended after four immersive days, November 26 to 29, of buzzing and breaking advancements across many healthcare subspecialties. Proud to be one of the 113 first-time RSNA exhibitors, VinBrain marks the first time a Vietnamese AI HealthTech start-up has participated in this biggest global Healthcare conference. “VinBrain's evolving product portfolio of AI solutions is being rapidly adopted by physicians,” said Prof. Dr. Gregory Moore, Associate Fellow Center for Artificial Intelligence and Medical Imaging (AIMI) at Stanford University School of Medicine, former Vice President of Microsoft Health global and Google Cloud Healthcare. VinBrain's presence at RSNA goes beyond mere company introduction; it's about learning from and aligning with fellow attendees in our shared mission to deliver high-quality diagnostic radiology care more efficiently and safely. VinBrain gained attention with new game-changers for radiologic AI and streamlining hospital operations. In the exclusive launch at 10:30 am (CT), November 27, the company has debuted two new game-changer solutions, encompassing DrAid™ Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid™ Oncology Diagnosis and Treatment (D&T). Expediting interoperability and streamlining, DrAid™ Enterprise Data Solution (EDS) is hoped to lead the healthcare transformation towards precision care. EDS brings a knowledge engine based on big data whose core is “to transfigure massive medical raw data into actionable knowledge and insights”, said Steven Truong, Founder & CEO VinBrain. EDS is capable of auto-generating reports multilingually in more than 25 languages. It helps doctors summarise examination history and highlight differences between reports and medical images. Besides, it provides personalised Electrical Medical Records Analytics and smart EMR search. For hospital operators, EDS delivers real-time insights through intuitive multi-dashboards and AI predictive analysis, empowering data-driven decisions for resource allocation. The excitement extends to DrAid™ Copilot - a medical AI-powered virtual assistant that helps healthcare professionals look up, extract data, and enhance productivity through natural language interaction. All the EDS modules are organised under the secure and centralised Data Lake and Data Management infrastructure, converting data to structured formats, and massive silos into a repository for world-class security and lasting and centralised storage for operative and R&D purposes. Oncology D&T, on the other hand, proves a broader adoption of AI to more accurate diagnosis and improved treatment decisions for the most complex diseases of mankind’s history. VinBrain is enlisted among the few pioneers in the world to develop a screening and treatment-aiding platform to empower the fight against liver and rectal cancer, two of the top 10 deadliest cancers in the world. The innovative AI-powered solutions, CT Liver Cancer D&T and MRI Rectal Cancer D&T reveal the intricacies of cancer classification, localisation, and measurement, enabling early detection and offering hope for saving more lives. Notably, CT Liver Cancer D&T can detect hepatocellular carcinoma (HCC), the most common liver malignancy. This solution utilises a novel method based on wavelet radiomics features from multiphase CT images for HCC screening. The study of this method was recently published in Nature Scientific Reports just ahead of RSNA 2023, coinciding with CT Liver Cancer D&T advancing to the final round of the ASEAN Digital Innovation 2023 Awards. The Oncology D&T utilises all the SOTA, including the nnUnet, ConvNeXt, and attention techniques. It is trained on and validated in high-quality and large datasets, confirmed by experienced radiologists. By providing comprehensive information, it aids oncologists in weighing treatment and surgery options such as surgical resection and transarterial chemoembolization (TACE), and total mesorectal excision (TME). Oncology D&T aim is to extend the life expectancy for a healthier life for patients and work as a second reader, while is beneficial to improve the workflow triage. Guided by a quality-first approach throughout our 4-year journey, VinBrain prioritises our strategic collaboration with esteemed institutions like Stanford University. As a guest speaker, Dr. Michael C. Muelly, Clinical Assistant Professor of Radiology at Stanford University, VinBrain’s Medical Partner shared: “I enjoyed spending time on the product launch. It's great to see what VinBrain is working up, very excited to see what is coming. The opportunities for AI to make big impacts around the world and medicine are huge. Viet Nam could be the place where it happens, starts, and spreads from there.” DrAid™’ can be easily integrated and deployed into many systems (PACS, HIS, RIS, EMR...), with the option of cloud or on-premises availability through the DrAid™ Appliance. VinBrain's team collaborates with NVIDIA biweekly to take advantage of NVIDIA's 48 GPUs, besides MONAI, and Tensor RT. DrAid™ adheres to HIPAA and NIST standards by employing Azure, ensuring robust privacy and security. At RSNA 2023, VinBrain also showcased its commitment to providing accessible healthcare in underserved regions with high tuberculosis burden through DrAid™ for Tuberculosis Screening (CXR Screening). This cost-effective solution enables large-scale screenings for an estimated 10.6 million TB-suspected individuals, garnering substantial praise from other exhibitors. Continue to learn and thrive! As Artificial Intelligence continues to make strides in radiology, such participation is a valued experience for VinBrain in every aspect including research and development, innovation and commercialisation capacity. With in-person fruitful discussions with nearly 500 visitors for four days, as well as witnessing 670 industry leaders at the Exhibits, VinBrain and its flagship product - DrAid™ has gained a lot of knowledge to reinforce the global expansion strategy and are poised to make a significant impact in the SEA, US, India, UK/EU, and Middle East markets between 2024 – 2027. About VinBrain VinBrain is a start-up that has been operating for four years and is backed by Vingroup, the largest conglomerate in Viet Nam. The company's mission is to integrate AI and IoT technologies to enhance people's lives and productivity. With an impressive portfolio of cutting-edge tech products and platforms, such as DrAid™ and AIScaler™, VinBrain has developed more than 300 AI models specifically designed for processing medical images. These models have been built using a dataset that comprises over 3.6 million images and extensive text-based big data from Viet Nam, the USA, India, China and Europe. Collaborated with leading organisations, institutes & and prestigious hospitals in Viet Nam and the United States, VinBrain's notable achievements include the deployment of DrAid™, a comprehensive AI platform for diagnostic radiology and healthcare management, in over 175 hospitals across Viet Nam, Myanmar, New Zealand, India, and the USA. For more information, press only: VinBrain JSC, info@vinbrain.net About RSNA RSNA® has over 48,110 members in 160 countries. The RSNA Scientific Assembly and Annual Meeting is the premier annual radiology forum in the world. It has been held consecutively in Chicago since 1985. The Technical Exhibits – AI Showcase within the framework of RSNA 2023, which occupied the North and South Hall of McCormick Place of 396,000 square feet and greatly immersed with 670 leading manufacturers, suppliers, and medical information and technology developers. It is the world’s largest scientific, educational, and commercial encounter for the wide array of latest healthcare innovations, and research in medical imaging, including artificial intelligence (AI), 3D printing, CT, MRI, and more. Contact Details VinBrain Phuong Nguyen, Marketing Manager +84 98 304 66 50 phuong.nguyen@vinbrain.net

December 04, 2023 08:30 AM Eastern Standard Time

Image

News Release

1606 Corp prepares for major launch of proprietary platform ChatCBDW chatbot

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news about the company's innovative chatbot, ChatCBDW. The chatbot, designed for the CBD industry, offers users the ability to ask questions about CBD and receive personalized product recommendations based on their needs. With a beta program underway, the company is collaborating with distribution partner Cool Blue Distribution and onboarding five beta customers to fine-tune the user experience and address any issues. Lambrecht says the pricing model includes three tiers at $299, $499, and $799, each offering varying levels of information. Lambrecht emphasized the significance of the beta testing phase in ironing out bugs and ensuring a smooth launch. The unique AI and merchandising chatbot positions 1606 Corp as a first mover in the industry. Looking ahead to January 2, 2024, the company plans an extensive marketing campaign for the official rollout. Lambrecht expressed confidence in the preparedness of their sales teams and emphasized the anticipation of a substantial response to the innovative product. Stay tuned for further updates on 1606 Corp's progress and new developments. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

November 30, 2023 12:23 PM Eastern Standard Time

Video

News Release

Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray

Evoke Pharma

Evoke Pharma CEO Dave Gonyer joined Steve Darling from Proactive to share news the company has achieved a significant milestone with the listing of its recently issued U.S. patent related to GIMOTI in the U.S. Food and Drug Administration's publication, commonly known as the "Orange Book." This development is of great importance as patents listed in the Orange Book cover drugs that the FDA has approved and deemed safe and effective for public use. The patent, titled "Nasal Formulations of Metoclopramide," pertains to a collection of nasal solutions of metoclopramide and outlines its characteristics when formulated. This newly listed patent in the FDA's Orange Book carries a patent term extending until 2029. Its inclusion adds an additional layer of patent protection for GIMOTI, complementing the three prior patents listed. This achievement underscores Evoke Pharma's commitment to advancing its innovative metoclopramide nasal spray, GIMOTI, which is designed to provide a treatment option for patients suffering from gastroparesis. The FDA's recognition of the patent's significance reaffirms GIMOTI's potential to address the unmet medical needs of patients. Furthermore, Gonyer shared insights into the company's recent financial performance, reporting a remarkable 38% increase compared to Q2 2023 and an impressive 88% increase year-over-year in Q3. These positive financial results set the stage for Evoke Pharma's ambitious growth plans for 2024. As Evoke Pharma continues to make strides in the pharmaceutical industry, its commitment to innovation, patient care, and expanding its patent portfolio positions the company for further success in the years ahead. Investors and stakeholders can look forward to the company's continued growth and contributions to improving patient outcomes. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 30, 2023 12:16 PM Eastern Standard Time

Video

PathAI Launches ArtifactDetect Model on AISight, Pioneering Automated Slide Quality Analysis in Pathology Labs

PathAI

PathAI, a leading digital and computational pathology company which provides precision pathology solutions has announced the availability of ArtifactDetect 1 on AISight ™ 2, PathAI’s digital pathology image management system. This product automates the detection of artifacts on digital pathology whole slide images and quantifies the extent of artifact on any WSI. Artifacts are unintentional morphological features that do not have any histopathological relevance. Artifacts can limit the utility of these images for review by pathologists and require replacement of the image, which can create delays in slide review and case turnaround time. The addition of ArtifactDetect to the menu of algorithms available through AISight broadens the set of efficiencies that are enabled through computational pathology and improved laboratory operations with a digital workflow. This technology automatically identifies poor-quality samples, allowing for timely interventions such as re-staining or re-scanning, thereby saving valuable resources on scanning tech, histotechnology, and pathologist time. This announcement addresses a crucial gap in pathology labs — the lack of a standardized slide quality control system. Pathologists often spend significant time reviewing non-evaluable slides due to the absence of established quality standards. With ArtifactDetect, PathAI aims to provide quality control and workflow optimization features, empowering pathology labs worldwide. “We are very excited to partner with PathAI to enhance automation and accuracy in our laboratories, benefiting both our operations and the value we bring to our beneficiaries,” remarked Dr. Fernando Soares, Full Professor at the University of Sao Paolo and Head of the Department of Anatomic Pathology at Rede D’Or. Rede D’Or is the largest integrated health network in Brazil with more than 70 hospitals and 55 oncology clinics in operation across more than ten states. “We have been testing the AIM-HER2 Breast Algorithm on our diverse cohorts to much success and are excited to expand our collaboration with PathAI to include algorithms that can drive workflow efficiencies and help us better track the quality of our whole slide images.” "The absence of a consistent slide quality standard leads to inefficiencies and challenges in pathology labs," says Dr. Eric Walk, Chief Medical Officer at PathAI. "Our goal is to distribute our advanced algorithms to foster a standardized approach, significantly reducing the time spent on non-evaluable slides." To learn more about AISight, PathAI’s Image Management System, ArtifactDetect or any of PathAI’s other algorithm product solutions, please visit https://www.pathai.com/ap-lab-solutions/ or request a meeting by contacting digitaldx@pathai.com. 1,2 ArtifactDetect and AISight are For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. About AISight AISight, introduced earlier this year by PathAI, is a comprehensive digital pathology image management system, currently offered for Research Use Only. AISight provides best-in-class image and case management, ingestion, and viewing while seamlessly enabling access and deployment of AI applications. AISight can also be integrated bidirectionally with laboratory information systems for streamlined workflow adoption. Anatomic pathology laboratories of all sizes and specialties – including health systems, reference laboratories, independent pathology labs, and academic medical centers – may utilize AISight. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 30, 2023 10:00 AM Eastern Standard Time

Image

Livespo Navax – World’s first spore probiotics in nasal spray form triumphs in ongoing clinical trials tackling influenza-related respiratory inflammation

LiveSpo

HANOI, VIETNAM - Media OutReach - 30 November 2023 - A recent publication in the Scientific Reports - Nature journal has once again highlighted the clinical trials of LiveSpo Navax spore probiotic spray. These trials focus on its effectiveness against respiratory tract inflammation from the influenza virus. This news marks a significant milestone for the Vietnamese medical sector, especially in setting a trend in global research and application of spore probiotics for respiratory well-being. Using a nasal spray with Bacillus probiotics in treating influenza patients has significantly reduced the total treatment time by up to 60 per cent (from five days for the control group to just two days for the spore probiotics spray group). Additionally, it increased treatment efficacy by 58 per cent, aiding in the complete recovery from symptoms such as runny nose, fever, sneezing, cough, rapid heartbeat, and rapid breathing. The decline in clinical symptoms corresponds with a drop in both viral and bacterial counts, notably decreasing by approximately 400 and 1,000 times on the second treatment day compared to the initial day of hospitalisation. The clinical trials confirm that the nasal spray containing Bacillus probiotics reduces treatment duration, lowering the chances of bacterial infection or severe respiratory tract complications. This not only helps cut treatment costs but also reduces antibiotic consumption for infections, fostering improved patient health. This positive signal is crucial for the medical community as it contributes to easing the burden on hospitals during disease outbreaks. Furthermore, the clinical trials indicate that the Bacillus probiotics, when formulated as a spray, offer superior effectiveness through interaction with the mucosal immune system of the nasal cavity. This means that the spore probiotics nasal spray not only supports the treatment of influenza-infected patients but also aids in treating respiratory tract inflammation caused by other viruses such as RSV, adenovirus, rhinovirus, coronavirus, etc. Regular use of Bacillus probiotics spray proves beneficial in enhancing the respiratory barrier, thereby boosting the effectiveness of virus-prevention vaccines. Probiotics, also known as a type of medicinal probiotics, serve as an effective solution in alleviating symptoms of respiratory diseases. In a previous study published in the Scientific Reports - Nature journal in July 2022, LiveSpo Navax supported the treatment of respiratory syncytial virus (RSV) in children. It significantly reduced the treatment time by more than one day and lowered the RSV concentration by over 600 times, surpassing the effectiveness of using physiological saline. This scientific research ranked among the top 100 downloaded microbiology articles in 2022 in the Nature Journal, demonstrating the widespread interest from scientists and readers worldwide and contributing significant values to the community. The two internationally validated clinical studies have confirmed that the LiveSpo Navax nasal spray, containing Bacillus probiotics, has demonstrated no side effects, guaranteeing complete safety for children. All patients using LiveSpo Navax in conjunction with standard treatment medications showed no signs of local bacterial infection or any digestive issues like vomiting, diarrhoea, or other abnormal symptoms. Therefore, in the future, this product will be fully suitable for inclusion in treatment plans for patients infected with respiratory viruses or bacteria. Dr. Nguyen Hoa Anh, Director of the Spore Probiotics Research Center shared: "We are proud to offer an effective support solution for patients with respiratory infections caused by viruses, bacteria, or acute inflammation. Moving forward, we will continue to research, develop, and bring the LiveSpo Navax product to consumers in Viet Nam and globally." With groundbreaking technology in spore probiotics - medicinal probiotics, LiveSpo Pharma aims to build a future free of antibiotics for everyone. Dang Quoc Hung, CEO of LiveSpo Pharma, stated: "At LiveSpo, we always strive to deliver the best products to our customers and the community. With the expertise of our scientific team, who have achieved notable research milestones in microbiology domestically and internationally, we are confident in developing and manufacturing effective and convenient spore probiotic products without side effects. This effort contributes to reducing antibiotic use and minimising antibiotic resistance in Viet Nam and the world. This is also LiveSpo's mission for development." As confirmed by the two successful publications in the prestigious Scientific Reports - Nature journal, LiveSpo has asserted its breakthrough in the products resulting from the company's extensive research and development efforts. LiveSpo takes pride in introducing Viet Nam's spore probiotics technology to the markets of developed countries which spearhead global medical advancements. This groundwork sets the stage for the future growth of Vietnamese enterprises, emphasising the expansion into global markets and the international promotion of Vietnamese brands and products. With a focus on product development, LiveSpo aims to create value for the community. The company's successful development of the Bacillus probiotics spray, which effectively aids respiratory disease treatment and minimises the risk of severe inflammation and prolonged antibiotic use, is helping pave the way toward a future less reliant on antibiotics. With its nature as a type of medical probiotic, LiveSpo products will help strengthen the natural immune barrier for the body when used over an extended period, thereby contributing to a community immune system if widely applied. This serves as a natural shield, protecting the community from diseases caused by viruses and bacteria. About LiveSpo Pharma LiveSpo is an R&D, manufacturing, and distribution brand of Spobiotics (probiotics in spore form) for digestive and respiratory health, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for "A Future Without Antibiotics". Hotline: 1800.088808 Website: livespo.com Contact Details Livespo Media Contact (Mr) Chu Minh Dac +84 98 459 95 96 dac.cm@livespo.com Company Website https://livespo.com/

November 30, 2023 08:55 AM Eastern Standard Time

Image

The Cultivated B Launches Next-Gen Bioreactor Remote Monitoring and Control Software

The Cultivated B

The Cultivated B (TCB) today announced the availability of its groundbreaking bioreactor control software, enabling a real-time, application-based, personalized user interface with added remote accessibility for its AUXO V® bioreactors. The software, now accessible via the control tower or remotely via phone- and web-based software, marks a significant leap forward in the cultivated meat industry, offering unparalleled convenience, flexibility and efficiency for expert and non-expert users to manage bioprocesses. TCB’s commercially available bioreactor, AUXO V, can be monitored and controlled by anyone, from any location with only a few days of training. “Our new bioreactor user interface embodies TCB’s commitment to innovation and flexibility for users, helping to scale the cultivated meat industry. Now, extremely complex processes can be run with the ease of a household device,” said The Cultivated B CEO Dr. Hamid Noori. “This technology is more than just a product; it's another proof point in our vision of a world where cultivated meat is easily accessible. In order to industrialize sustainable protein production, it is essential that a larger workforce can be trained on new processes, rather than building operations around experts only. We believe that by simplifying the monitoring and control of the production process and making it accessible anywhere at any time, we can significantly accelerate the pace at which cultivated meat reaches mass adoption.” The new bioreactor control software is tailored to meet the diverse needs of user groups with different experience levels, including existing as well as new user groups. Remote monitoring benefits include: Increased flexibility – Choose between direct or remote control of bioprocesses Sustained monitoring – 24/7 availability allows rapid intervention in the event of irregularities Optimized allocation of workforce – Eliminate the need for users to remain onsite by automating processes The next-generation monitoring is not just a technological advancement but also a strategic response to the global shortage of know-how and skilled workers needed to scale the cultivated meat industry. TCB equips the AUXO V bioreactor with an innovative user interface featuring three levels of detail: Operate – Pre-programmed recipes allow seamless operation for non-experts Explore – Adjust key parameters at detailed levels (e.g., temperature, pH, oxygen) Develop– Access collected data outside of the production cycle to refine and further enhance your individual process TCB announced earlier this year the start of manufacturing at the company’s Burlington, Ontario plant. With an interdisciplinary team of scientists and engineers, TCB refined the production of its AUXO V from lab scale to industrial scale. The multi-use bioreactors are cost-effective, flexible and customizable, designed to offer a unique combination of utility and sustainability. They are equipped with multiple sensors and optimized impellers for different organisms, such as avian and mammalian cells, bacteria or yeast. Short delivery times, modular design and a customer-centric control system make the AUXO V bioreactor a huge accelerator, equipped with novel technology for quick adoption in a rapidly changing market environment. About The Cultivated B (TCB) The Cultivated B’s multinational team of scientists develops and applies breakthrough technologies in cellular agriculture, precision fermentation and advanced bioreactor technology to enable scalable commercialization of the cellular-agriculture industry. TCB serves startups, corporations and academic research institutions within the food, pharma, cosmetics and personal care industries. With its pioneering engineering and production capabilities, TCB enables other companies to produce alternative proteins, such as cultivated meat, at industrial scale. The company’s fundamental commitment to minimizing the natural resources used paves the way toward a sustainable future, locally, regionally and globally. TCB’s research and development team is based in Germany, with manufacturing and an innovation hub based in Canada’s Toronto region. For more information, visit https://www.thecultivatedb.com and follow the company on LinkedIn. Contact Details Jenna Beaucage +1 508-340-6851 tcb@rainerco.com Company Website https://www.thecultivatedb.com

November 30, 2023 08:07 AM Eastern Standard Time

Image

News Release

Filament Health announces non-binding agreement for up to US$14 million in financing

Filament Health Corp

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to announce the signing of a non-binding term sheet for potential funding of up to US$14.4 million. The funding is in collaboration with an affiliate of Helena Partners Inc., a Cayman-Islands-based advisor and investor. The infusion of capital is expected to significantly bolster Filament Health's operations, particularly in advancing its drug development programs. Furthermore, this funding will play a crucial role in facilitating the completion of the Proposed Business Combination with the Jupiter Acquisition Corporation. Notably, it is a strategic step towards achieving the company's goal of listing on the Nasdaq stock exchange. This financial boost demonstrates Filament Health's commitment to driving innovation in the pharmaceutical sector and expanding its presence in the financial markets. Stay tuned for more updates on Filament Health's exciting journey ahead. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 29, 2023 01:57 PM Eastern Standard Time

Video